title: Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications.
abstract: The dysregulation of membrane phospholipid metabolism exists throughout the body from the onset of psychosis in schizophrenic patients. This dysregulation is primarily due to altered contents of phospholipid bound EPUFAs, AA and DHA. These EPUFAs are highly enriched in the brain and are crucial for brain and behavioral development. A phospholipid metabolic defect may preexist the onset of psychosis, even through early embryonic stages. Because these membrane phospholipids play a crucial role in the membrane receptor-mediated signal transduction of several neuro-transmitters and growth factors, their altered metabolism may contribute to the reported abnormal information processing in schizophrenia. Severity of symptoms seems to correlate with the membrane AA and DHA status, which is influenced by patients' dietary intake and lifestyle. Such a metabolic defect can be prevented, however, and some membrane pathology can be corrected by dietary supplementation with a combination of AA and DHA and antioxidants such as vitamins E and C. In schizophrenia, it may be advisable to provide supplementation at the early stages of illness, when brain has a high degree of plasticity. Finally, at this time, supplementation has to be considered as an augmentation of conventional antipsychotic treatment.
authors.affiliation: Department of Psychiatry, Medical College of Georgia, Augusta, GA, USA. mahadik@psychnts4.mcg.edu
authors.forename: Sahebarao P
authors.initials: SP
authors.lastname: Mahadik
authors.forename: Denise R
authors.initials: DR
authors.lastname: Evans
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology*; D001928:Brain Diseases, Metabolic / Q000378:metabolism / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008563:Membrane Lipids / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D010743:Phospholipids / Q000096:biosynthesis*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D008563:Membrane Lipids; D010743:Phospholipids